Director/PDMR Shareholding

Cambridge, UK, 1 May 2015: Sphere Medical Holding plc (AIM: SPHR.L), (“Sphere Medical” or the “Company”) a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that 82,352,582 New Ordinary Shares issued in connection with the Placing and Open Offer have today been admitted to trading on AIM. 

Following Admission, the Company now has 141,757,872 Ordinary Shares in issue.  This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the AIM Rules.

Directors’ Shareholdings

Following the announcements made on 29 April 2015 and pursuant to the Fundraising and as referred to in the Company’s circular to shareholders dated 13 April 2015, certain of the Directors have subscribed for New Ordinary Shares in the Placing and / or Open Offer at the issue price of 16 pence per share.  The number of New Ordinary Shares each Director subscribed for pursuant to the Placing and / or the Open Offer and their corresponding shareholdings immediately following Admission, are set out below:

Name of Director

Number of Open Offer Shares subscribed for (as announced on 29 April 2015)

Number of Placing Shares subscribed for

Total holding of Ordinary Shares immediately following Admission

Percentage of issued share capital immediately following Admission

Dr Anthony Martin

187,500

-

417,554

0.29%

Dr Wolfgang Rencken

218,750

218,750

449,470

0.32%

John Gregory

46,875

-

90,745

0.06%

Stephen H. Mahle

93,750

-

152,888

0.11%

Meinhard Schmidt

-

187,500

187,500

0.13%

Dr David Martyr

-

125,000

125,000

0.09%

Grant of Share Options

The following share options were granted on 1 May 2015, pursuant to Share Option Schemes, to the following Directors:

Name of Director

Number of Share Options Granted

Exercise Price

Dr Wolfgang Rencken, CEO

2,260,000

16 pence

Matthew Hall, CFO

1,340,000

16 pence

Dr Anthony Martin, Non-Executive Chairman

100,000

16 pence

Mr John Gregory, Non-Executive Director

100,000

16 pence

Mr Stephen Mahle, Non-Executive Director

100,000

16 pence

Dr David Martyr, Non-Executive Director

100,000

16 pence

Mr Meinhard Schmidt, Non-Executive Director

100,000

16 pence

 

All share options were issued under the Company's Unapproved Share Option Scheme and are exercisable over ordinary shares of 1 pence each in the share capital of the Company.  The exercise price of 16 pence equates to the Issue Price of the Placing and Open Offer.

These share options are subject to vesting conditions and a minimum holding period of five years from grant.  The issue of these share options has been approved by the Company's Remuneration Committee.

Appointment of new Non-Executive Director

The Company is pleased to announce the appointment of Mr Brenig Gwilym Preest (aged 42) as a Non-Executive Director of the Company with immediate effect.

Mr Preest has spent over 15 years in the investment and corporate finance sector, primarily investing in high growth medical technology and biotechnology opportunities and has been involved with over £500m of investments.  His early career was at Amersham International (now GE Healthcare) and Coopers & Lybrand (now PwC) and is currently an investment director at Arthurian Life Sciences Limited, a venture capital firm, which provides management services to the Wales Life Sciences Investment Fund LP (being a fund raising up to £100 million focused on life sciences).  Mr Preest is a chartered accountant, studied Pharmacology at Cardiff University, Financial Strategy at Oxford University and was previously elected regional president for the ICAEW.

Mr Preest has not held any directorships within the past 5 years, however, Mr Preest has previously been a director of Abcellute Limited (dissolved), Dragon Digital Intermediate Limited and Nightingale Care Bed Holdings Limited. No further information is required to be disclosed under Rule 17 of the AIM Rules.

Change of Registered Office

In accordance with the terms of the side letter between Arthurian Life Sciences Limited and the Company dated 13 April 2015, the Company has changed its registered office with immediate effect to the following address: Life Sciences Hub Wales, 3 Assembly Square, Cardiff CF10 4PL.